Regan Andrew

SEC source: 0001753926-26-001698 · ownership.xml · derivative · entry 6

Regan Andrew · CIK 0001991325 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Corvus Capital Ltd.

Disclosed balance after: 0

Underlying: Common Stock · 5,436,830 shares

Expires not disclosed

F1 · shares: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · shares: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F3 · shares: These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

F7 · derivative.expiration_date: The Pre-Funded Warrants have been exercised in full.

F1 · derivative.underlying_shares: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · derivative.underlying_shares: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F3 · derivative.underlying_shares: These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

F1 · balance_after: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · balance_after: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F3 · balance_after: These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

F4 · ownership.nature: Corvus is the owner of 99.0% of the equity interests of Manoira Corporation ("Manoira") and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Andrew Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock and Pre-Funded Warrants held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

SEC source: 0001753926-26-001698 · ownership.xml · nonDerivative · entry 2

Regan Andrew · CIK 0001991325 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Corvus Capital Ltd.

Disclosed balance after: 5,692,933

F1 · kind: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · kind: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F6 · kind: Corvus exercised the Pre-Funded Warrants on a cashless basis, which resulted in the Issuer withholding 290 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants to pay the exercise price.

F1 · shares: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · shares: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F6 · shares: Corvus exercised the Pre-Funded Warrants on a cashless basis, which resulted in the Issuer withholding 290 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants to pay the exercise price.

F1 · price: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · price: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F3 · ownership.nature: These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

F4 · ownership.nature: Corvus is the owner of 99.0% of the equity interests of Manoira Corporation ("Manoira") and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Andrew Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock and Pre-Funded Warrants held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

SEC source: 0001753926-26-001698 · ownership.xml · nonDerivative · entry 1

Regan Andrew · CIK 0001991325 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Corvus Capital Ltd.

Disclosed balance after: 5,693,223

F1 · shares: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · shares: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F1 · price: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · price: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F3 · ownership.nature: These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

F4 · ownership.nature: Corvus is the owner of 99.0% of the equity interests of Manoira Corporation ("Manoira") and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Andrew Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock and Pre-Funded Warrants held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

SEC source: 0001753926-26-001698 · ownership.xml · derivative · entry 5

Regan Andrew · CIK 0001991325 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Corvus Capital Ltd.

Disclosed balance after: 5,436,830

Underlying: Common Stock · 5,436,830 shares

Expires not disclosed

F1 · kind: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · kind: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F1 · shares: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · shares: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F3 · shares: These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

F1 · derivative.exercise_date: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · derivative.exercise_date: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F7 · derivative.expiration_date: The Pre-Funded Warrants have been exercised in full.

F1 · derivative.underlying_shares: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · derivative.underlying_shares: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F3 · derivative.underlying_shares: These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

F1 · balance_after: On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

F2 · balance_after: The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

F3 · balance_after: These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

F4 · ownership.nature: Corvus is the owner of 99.0% of the equity interests of Manoira Corporation ("Manoira") and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Andrew Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock and Pre-Funded Warrants held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

SEC source: 0001753926-26-000867 · ownership.xml · nonDerivative · entry 2

Regan Andrew · CIK 0001991325 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Corvus Capital Ltd.

Disclosed balance after: 256,393

F4 · shares: On May 13, 2026, Corvus purchased a total of 100,000 shares of Common Stock in the open market at a price per share of $1.90 for total cash consideration of $190,000.

F4 · price: On May 13, 2026, Corvus purchased a total of 100,000 shares of Common Stock in the open market at a price per share of $1.90 for total cash consideration of $190,000.

F3 · ownership.nature: These shares of Common Stock are owned of record by Corvus.

F6 · ownership.nature: Corvus is the owner of 99.0% of the equity interests of Manoira and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

SEC source: 0001753926-26-000867 · ownership.xml · derivative · entry 5

Regan Andrew · CIK 0001991325 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Corvus Capital Ltd.

Disclosed balance after: 0

Underlying: Common Stock · 147,401 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On March 26, 2026, CDT Equity Inc. (the "Company") effected a 1-for-25 reverse stock split (the "Reverse Stock Split") of the Company's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Corvus ceased to be a 10% holder as of February 19, 2026.

F2 · shares: On March 24, 2026, Corvus Capital Limited ("Corvus") exercised all its pre-funded warrants (the "Pre-Funded Warrants") via cashless exercise for 147,401 shares of Common Stock.

F7 · derivative.expiration_date: The Pre-Funded Warrants have been exercised in full.

F1 · derivative.underlying_shares: On March 26, 2026, CDT Equity Inc. (the "Company") effected a 1-for-25 reverse stock split (the "Reverse Stock Split") of the Company's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Corvus ceased to be a 10% holder as of February 19, 2026.

F2 · derivative.underlying_shares: On March 24, 2026, Corvus Capital Limited ("Corvus") exercised all its pre-funded warrants (the "Pre-Funded Warrants") via cashless exercise for 147,401 shares of Common Stock.

F1 · balance_after: On March 26, 2026, CDT Equity Inc. (the "Company") effected a 1-for-25 reverse stock split (the "Reverse Stock Split") of the Company's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Corvus ceased to be a 10% holder as of February 19, 2026.

F2 · balance_after: On March 24, 2026, Corvus Capital Limited ("Corvus") exercised all its pre-funded warrants (the "Pre-Funded Warrants") via cashless exercise for 147,401 shares of Common Stock.

F3 · ownership.nature: These shares of Common Stock are owned of record by Corvus.

F6 · ownership.nature: Corvus is the owner of 99.0% of the equity interests of Manoira and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

SEC source: 0001753926-26-000867 · ownership.xml · nonDerivative · entry 1

Regan Andrew · CIK 0001991325 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Corvus Capital Ltd.

Disclosed balance after: 156,393

F1 · shares: On March 26, 2026, CDT Equity Inc. (the "Company") effected a 1-for-25 reverse stock split (the "Reverse Stock Split") of the Company's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Corvus ceased to be a 10% holder as of February 19, 2026.

F2 · shares: On March 24, 2026, Corvus Capital Limited ("Corvus") exercised all its pre-funded warrants (the "Pre-Funded Warrants") via cashless exercise for 147,401 shares of Common Stock.

F2 · price: On March 24, 2026, Corvus Capital Limited ("Corvus") exercised all its pre-funded warrants (the "Pre-Funded Warrants") via cashless exercise for 147,401 shares of Common Stock.

F3 · ownership.nature: These shares of Common Stock are owned of record by Corvus.

F6 · ownership.nature: Corvus is the owner of 99.0% of the equity interests of Manoira and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

SEC source: 0001493152-25-028761 · ownership.xml · derivative · entry 5

Regan Andrew · CIK 0001991325 · Director · Chief Executive Officer · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Corvus Capital Ltd.

Disclosed balance after: 3,685,815

Underlying: Common Stock · 3,685,815 shares

Expires not disclosed

F1 · shares: On December 8, 2025, CDT Equity Inc. (the "Company") and Corvus Capital Limited ("Corvus") entered into a Sale and Purchase Agreement, pursuant to which the Company issued to Corvus 224,800 shares of common stock, par value $0.0001 per share of the Company, and pre-funded warrants to purchase up to 3,685,815 shares of Common Stock (the "Pre-Funded Warrants"), pursuant to the acquisition of Conduit Pharmaceuticals Limited and its liabilities.

F7 · derivative.expiration_date: Until exercised in full.

F1 · derivative.underlying_shares: On December 8, 2025, CDT Equity Inc. (the "Company") and Corvus Capital Limited ("Corvus") entered into a Sale and Purchase Agreement, pursuant to which the Company issued to Corvus 224,800 shares of common stock, par value $0.0001 per share of the Company, and pre-funded warrants to purchase up to 3,685,815 shares of Common Stock (the "Pre-Funded Warrants"), pursuant to the acquisition of Conduit Pharmaceuticals Limited and its liabilities.

F1 · balance_after: On December 8, 2025, CDT Equity Inc. (the "Company") and Corvus Capital Limited ("Corvus") entered into a Sale and Purchase Agreement, pursuant to which the Company issued to Corvus 224,800 shares of common stock, par value $0.0001 per share of the Company, and pre-funded warrants to purchase up to 3,685,815 shares of Common Stock (the "Pre-Funded Warrants"), pursuant to the acquisition of Conduit Pharmaceuticals Limited and its liabilities.

F3 · ownership.nature: These shares of Common Stock are owned of record by Corvus.

F6 · ownership.nature: Corvus is the owner of 99.0% of the equity interests of Manoira and Algo is a wholly owned subsidiary of Corvus, and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira and Algo. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira, Algo and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, including with respect to the Pre-Funded Warrant Shares, except to the extent of its or his pecuniary interest therein.

SEC source: 0001493152-25-028761 · ownership.xml · nonDerivative · entry 1

Regan Andrew · CIK 0001991325 · Director · Chief Executive Officer · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Corvus Capital Ltd.

Disclosed balance after: 227,304

F1 · shares: On December 8, 2025, CDT Equity Inc. (the "Company") and Corvus Capital Limited ("Corvus") entered into a Sale and Purchase Agreement, pursuant to which the Company issued to Corvus 224,800 shares of common stock, par value $0.0001 per share of the Company, and pre-funded warrants to purchase up to 3,685,815 shares of Common Stock (the "Pre-Funded Warrants"), pursuant to the acquisition of Conduit Pharmaceuticals Limited and its liabilities.

F2 · price: Based on the closing price per share of Common Stock on December 7, 2025.

F3 · ownership.nature: These shares of Common Stock are owned of record by Corvus.

F6 · ownership.nature: Corvus is the owner of 99.0% of the equity interests of Manoira and Algo is a wholly owned subsidiary of Corvus, and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira and Algo. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira, Algo and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, including with respect to the Pre-Funded Warrant Shares, except to the extent of its or his pecuniary interest therein.

SEC source: 0001493152-25-014477 · ownership.xml · nonDerivative · entry 1

Regan Andrew · CIK 0001991325 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,120,044

F1 · shares: On September 19, 2025, CDT Equity Inc. (formerly known as Conduit Pharmaceuticals Inc. (the "Issuer")) granted Dr. Andrew Regan ("Dr. Regan") 1,120,000 shares of common stock, par value $0.0001 ("Common Stock"), of the Issuer pursuant to the Issuer's Amended and Restated 2023 Stock Incentive Plan as compensation for his services as a director and an officer of the Issuer.

F2 · price: Based on the closing price per share of Common Stock on September 18, 2025.

SEC source: 0001641172-25-014963 · ownership.xml · nonDerivative · entry 1

Regan Andrew · CIK 0001991325 · Director · Chief Executive Officer · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 154,799

F1 · price: Based on the closing price per share of the Issuer's common stock, par value $0.0001 ("Common Stock"), on June 3, 2025.

F2 · ownership.nature: These shares of Common Stock are owned of record by Manoira Corporation ("Manoira"). On June 3, 2025, the Issuer issued 154,799 shares of Common Stock to Manoira pursuant to that certain joint development agreement (the "Joint Development Agreement") by and between the Issuer and Manoira, representing an up-front consideration of $500,000.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 12

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 177,627

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.255-0.265, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range. Following the sales of shares of Common Stock as reported in this Form 4, Algo no longer holds 10% of the outstanding shares of Common Stock of the Issuer.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 11

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,691,727

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.247-0.405, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 10

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 11,936,119

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.223-0.276, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 9

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 12,941,319

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.266-0.303, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 8

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 14,331,139

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.279-0.307, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 7

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 14,631,139

F6 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.290-0.307, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 6

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,214,091

F5 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.307-0.371, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 5

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,364,091

F4 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were sold in multiple transactions at prices ranging from $0.426-0.452, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 4

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,441,772

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 3

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,477,695

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 2

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 15,478,695

F1 · price: On June 14, 2024, Corvus Capital Limited ("Corvus") transferred 1,100,000 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), to Algo Holdings, Inc. ("Algo"), its wholly-owned subsidiary for no consideration, pursuant to that certain Securities Transfer Request dated June 13, 2024. After giving effect to the transfer, Algo directly held 15,478,695 shares of Common Stock as of June 14, 2024. Andrew Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. This transfer reflects a change in the form of beneficial ownership and did not result in any change in Dr. Regan's and Corvus's pecuniary interest in such shares.

F1 · ownership.nature: On June 14, 2024, Corvus Capital Limited ("Corvus") transferred 1,100,000 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), to Algo Holdings, Inc. ("Algo"), its wholly-owned subsidiary for no consideration, pursuant to that certain Securities Transfer Request dated June 13, 2024. After giving effect to the transfer, Algo directly held 15,478,695 shares of Common Stock as of June 14, 2024. Andrew Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. This transfer reflects a change in the form of beneficial ownership and did not result in any change in Dr. Regan's and Corvus's pecuniary interest in such shares.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

SEC source: 0001493152-24-037150 · ownership.xml · nonDerivative · entry 1

Regan Andrew · CIK 0001991325 · Director · 10% owner

Corvus Capital Ltd. · CIK 0001990829 · 10% owner

Algo Holdings, Inc. · CIK 0001991236 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 30,048,454

F1 · price: On June 14, 2024, Corvus Capital Limited ("Corvus") transferred 1,100,000 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), to Algo Holdings, Inc. ("Algo"), its wholly-owned subsidiary for no consideration, pursuant to that certain Securities Transfer Request dated June 13, 2024. After giving effect to the transfer, Algo directly held 15,478,695 shares of Common Stock as of June 14, 2024. Andrew Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. This transfer reflects a change in the form of beneficial ownership and did not result in any change in Dr. Regan's and Corvus's pecuniary interest in such shares.

F1 · ownership.nature: On June 14, 2024, Corvus Capital Limited ("Corvus") transferred 1,100,000 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), to Algo Holdings, Inc. ("Algo"), its wholly-owned subsidiary for no consideration, pursuant to that certain Securities Transfer Request dated June 13, 2024. After giving effect to the transfer, Algo directly held 15,478,695 shares of Common Stock as of June 14, 2024. Andrew Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. This transfer reflects a change in the form of beneficial ownership and did not result in any change in Dr. Regan's and Corvus's pecuniary interest in such shares.

F2 · ownership.nature: Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.